“Castle Biosciences is focused on delivering high value tests to improve cancer treatment. This expanded capital facility will be used to accelerate growth of our cutaneous melanoma test, DecisionDx®-Melanoma, and support our near-term pipeline,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.Continue reading
Author Archive: AZBio
VisionGate Seeks to Diagnose and Prevent Lung Cancer
Congresswoman Kyrsten Sinema visits Phoenix Arizona based VisionGate to meet with employees and learn about this innovative life science company.Continue reading
TGen distinguished professor honored by New York’s Columbia University
Dr. Daniel Von Hoff recognized by alumni of Columbia’s College of Physicians and Surgeons for excellence in clinical medicine
University of Arizona Startups Draw Silicon Valley Attention to Tucson
TUCSON, Ariz. and MOUNTAIN VIEW, Calif. – On May 3, four startups founded on inventions based on University of Arizona research made their pitches at an accelerator in one of the nation’s epicenters for technology and entrepreneurship: Silicon Valley.Continue reading
A Bit About Budgets – News from Washington DC to Washington Street
Last week was a busy week on the Budget Front as President Trump signed a $1 Trillion spending package that funds the federal overnment through the end of September and the Arizona Legislature sent its $9.8 Billion Budget Packet to Governor Ducey. Both spending plans send a strong message that research matters.Continue reading
HTG Molecular Diagnostics Introduces HTG EdgeSeq PATH Assay to Launch in Second Quarter 2017
On May 4, 2017, HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that its new HTG EdgeSeq PATH Assay is expected to be available for research uses by the end of the second quarter of 2017.Continue reading
One Billion Reasons Why University Research Has a Brighter Future in Arizona
The Arizona Legislature has voted to approve a plan to invest $1 Billion in Arizona’s University Research Infrastructure.
Continue reading
Critical Path Institute and TGen forge partnership to advance TB research
TUCSON and FLAGSTAFF, Ariz. — May 1, 2017 — The Critical Path to TB Drug Regimens (CPTR), an initiative of the Critical Path Institute (C-Path), has received a $1.1 million grant from the Bill & Melinda Gates Foundation to significantly enrich its Relational Sequencing TB Data Platform (ReSeqTB).
HealthTell, Inc. Launches New Pre-Clinical Services Business
An Efficient, Information Rich, High-Throughput Platform to Characterize Antibodies, with a Vision for New Drug Discovery